The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...

A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap, while ...

Now, this won't come as too much of a surprise to Eli Lilly and its peers. A few weeks ago, the company's CEO, David Ricks, ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co. (LLY), GE Aerospace ...

Eli Lilly and Company (NYSE:LLY) is a leading medicine company which discovers, develops, manufactures, and markets products ...

As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have ...

Eli Lilly (NYSE:LLY) said Thursday that Ilya Yuffa, executive vice president and president, Lilly International, will become executive vice president and president, Lilly USA and Global Customer ...

Eli Lilly and Co (NYSE:LLY) reported a 45% increase in revenue compared to Q1 2024, driven by key products such as Mounjaro and Zepbound. The company achieved several key pipeline milestones ...

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

Eli Lilly and Co. on Thursday announced three executive leadership transitions that the Indianapolis drugmaker said better position the company for growth, particularly for growth in U.S. investment ...

Eli Lilly and Company’s LLY shares have lost 17% so far in May. Lilly announced mixed earnings results on May 1. It missed ...